Report Detail
Global Paroxysmal Nocturnal Hemoglobinuria Treatment Market Insights, Forecast to 2025
- RnM2997001 |
- 22 February, 2019 |
- Global |
- 119 Pages |
- QYResearch |
- Pharma & Healthcare
The global Paroxysmal Nocturnal Hemoglobinuria Treatment market is valued at million US$ in 2018 and will reach million US$ by the end of 2025, growing at a CAGR of during 2019-2025. The objectives of this study are to define, segment, and project the size of the Paroxysmal Nocturnal Hemoglobinuria Treatment market based on company, product type, end user and key regions.
This report studies the global market size of Paroxysmal Nocturnal Hemoglobinuria Treatment in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Paroxysmal Nocturnal Hemoglobinuria Treatment in these regions.
This research report categorizes the global Paroxysmal Nocturnal Hemoglobinuria Treatment market by top players/brands, region, type and end user. This report also studies the global Paroxysmal Nocturnal Hemoglobinuria Treatment market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.
The following manufacturers are covered in this report, with sales, revenue, market share for each company:
Achillion Pharmaceuticals Inc
Akari Therapeutics Plc
Alexion Pharmaceuticals Inc
Alnylam Pharmaceuticals Inc
Amgen Inc
Apellis Pharmaceuticals Inc
F. Hoffmann-La Roche Ltd
ISU ABXIS Co Ltd
Novartis AG
NovelMed Therapeutics Inc
Omeros Corp
Ra Pharmaceuticals Inc
Regeneron Pharmaceuticals Inc
Regenesance BV
Market size by Product
ACH-4471
ALN-CC5
ALXN-1210
AMY-101
APL-2
Others
Market size by End User
Hospital
Clinic
Others
Market size by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
India
Japan
South Korea
Australia
Indonesia
Singapore
Malaysia
Philippines
Thailand
Vietnam
Europe
Germany
France
UK
Italy
Spain
Russia
Central & South America
Brazil
Rest of Central & South America
Middle East & Africa
GCC Countries
Turkey
Egypt
South Africa
The study objectives of this report are:
To study and analyze the global Paroxysmal Nocturnal Hemoglobinuria Treatment market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
To understand the structure of Paroxysmal Nocturnal Hemoglobinuria Treatment market by identifying its various subsegments.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
Focuses on the key global Paroxysmal Nocturnal Hemoglobinuria Treatment companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
To project the value and sales volume of Paroxysmal Nocturnal Hemoglobinuria Treatment submarkets, with respect to key regions.
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
In this study, the years considered to estimate the market size of Paroxysmal Nocturnal Hemoglobinuria Treatment are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
This report includes the estimation of market size for value (million US$) and volume (K Pcs). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Paroxysmal Nocturnal Hemoglobinuria Treatment market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.
For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.
Table of Contents
1 Study Coverage
- 1.1 Paroxysmal Nocturnal Hemoglobinuria Treatment Product
- 1.2 Market Segments
- 1.3 Key Manufacturers Covered
- 1.4 Market by Type
- 1.4.1 Global Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size Growth Rate by Product
- 1.4.2 ACH-4471
- 1.4.3 ALN-CC5
- 1.4.4 ALXN-1210
- 1.4.5 AMY-101
- 1.4.6 APL-2
- 1.4.7 Others
- 1.5 Market by End User
- 1.5.1 Global Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size Growth Rate by End User
- 1.5.2 Hospital
- 1.5.3 Clinic
- 1.5.4 Others
- 1.6 Study Objectives
- 1.7 Years Considered
2 Executive Summary
- 2.1 Global Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size
- 2.1.1 Global Paroxysmal Nocturnal Hemoglobinuria Treatment Revenue 2014-2025
- 2.1.2 Global Paroxysmal Nocturnal Hemoglobinuria Treatment Sales 2014-2025
- 2.2 Paroxysmal Nocturnal Hemoglobinuria Treatment Growth Rate by Regions
- 2.2.1 Global Paroxysmal Nocturnal Hemoglobinuria Treatment Sales by Regions
- 2.2.2 Global Paroxysmal Nocturnal Hemoglobinuria Treatment Revenue by Regions
3 Breakdown Data by Manufacturers
- 3.1 Paroxysmal Nocturnal Hemoglobinuria Treatment Sales by Manufacturers
- 3.1.1 Paroxysmal Nocturnal Hemoglobinuria Treatment Sales by Manufacturers
- 3.1.2 Paroxysmal Nocturnal Hemoglobinuria Treatment Sales Market Share by Manufacturers
- 3.1.3 Global Paroxysmal Nocturnal Hemoglobinuria Treatment Market Concentration Ratio (CR5 and HHI)
- 3.2 Paroxysmal Nocturnal Hemoglobinuria Treatment Revenue by Manufacturers
- 3.2.1 Paroxysmal Nocturnal Hemoglobinuria Treatment Revenue by Manufacturers (2014-2019)
- 3.2.2 Paroxysmal Nocturnal Hemoglobinuria Treatment Revenue Share by Manufacturers (2014-2019)
- 3.3 Paroxysmal Nocturnal Hemoglobinuria Treatment Price by Manufacturers
- 3.4 Paroxysmal Nocturnal Hemoglobinuria Treatment Manufacturing Base Distribution, Product Types
- 3.4.1 Paroxysmal Nocturnal Hemoglobinuria Treatment Manufacturers Manufacturing Base Distribution, Headquarters
- 3.4.2 Manufacturers Paroxysmal Nocturnal Hemoglobinuria Treatment Product Type
- 3.4.3 Date of International Manufacturers Enter into Paroxysmal Nocturnal Hemoglobinuria Treatment Market
- 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans
4 Breakdown Data by Product
- 4.1 Global Paroxysmal Nocturnal Hemoglobinuria Treatment Sales by Product
- 4.2 Global Paroxysmal Nocturnal Hemoglobinuria Treatment Revenue by Product
- 4.3 Paroxysmal Nocturnal Hemoglobinuria Treatment Price by Product
5 Breakdown Data by End User
- 5.1 Overview
- 5.2 Global Paroxysmal Nocturnal Hemoglobinuria Treatment Breakdown Data by End User
6 North America
- 6.1 North America Paroxysmal Nocturnal Hemoglobinuria Treatment by Countries
- 6.1.1 North America Paroxysmal Nocturnal Hemoglobinuria Treatment Sales by Countries
- 6.1.2 North America Paroxysmal Nocturnal Hemoglobinuria Treatment Revenue by Countries
- 6.1.3 United States
- 6.1.4 Canada
- 6.1.5 Mexico
- 6.2 North America Paroxysmal Nocturnal Hemoglobinuria Treatment by Product
- 6.3 North America Paroxysmal Nocturnal Hemoglobinuria Treatment by End User
7 Europe
- 7.1 Europe Paroxysmal Nocturnal Hemoglobinuria Treatment by Countries
- 7.1.1 Europe Paroxysmal Nocturnal Hemoglobinuria Treatment Sales by Countries
- 7.1.2 Europe Paroxysmal Nocturnal Hemoglobinuria Treatment Revenue by Countries
- 7.1.3 Germany
- 7.1.4 France
- 7.1.5 UK
- 7.1.6 Italy
- 7.1.7 Russia
- 7.2 Europe Paroxysmal Nocturnal Hemoglobinuria Treatment by Product
- 7.3 Europe Paroxysmal Nocturnal Hemoglobinuria Treatment by End User
8 Asia Pacific
- 8.1 Asia Pacific Paroxysmal Nocturnal Hemoglobinuria Treatment by Countries
- 8.1.1 Asia Pacific Paroxysmal Nocturnal Hemoglobinuria Treatment Sales by Countries
- 8.1.2 Asia Pacific Paroxysmal Nocturnal Hemoglobinuria Treatment Revenue by Countries
- 8.1.3 China
- 8.1.4 Japan
- 8.1.5 Korea
- 8.1.6 India
- 8.1.7 Australia
- 8.1.8 Indonesia
- 8.1.9 Malaysia
- 8.1.10 Philippines
- 8.1.11 Thailand
- 8.1.12 Vietnam
- 8.1.13 Singapore
- 8.2 Asia Pacific Paroxysmal Nocturnal Hemoglobinuria Treatment by Product
- 8.3 Asia Pacific Paroxysmal Nocturnal Hemoglobinuria Treatment by End User
9 Central & South America
- 9.1 Central & South America Paroxysmal Nocturnal Hemoglobinuria Treatment by Countries
- 9.1.1 Central & South America Paroxysmal Nocturnal Hemoglobinuria Treatment Sales by Countries
- 9.1.2 Central & South America Paroxysmal Nocturnal Hemoglobinuria Treatment Revenue by Countries
- 9.1.3 Brazil
- 9.2 Central & South America Paroxysmal Nocturnal Hemoglobinuria Treatment by Product
- 9.3 Central & South America Paroxysmal Nocturnal Hemoglobinuria Treatment by End User
10 Middle East and Africa
- 10.1 Middle East and Africa Paroxysmal Nocturnal Hemoglobinuria Treatment by Countries
- 10.1.1 Middle East and Africa Paroxysmal Nocturnal Hemoglobinuria Treatment Sales by Countries
- 10.1.2 Middle East and Africa Paroxysmal Nocturnal Hemoglobinuria Treatment Revenue by Countries
- 10.1.3 GCC Countries
- 10.1.4 Turkey
- 10.1.5 Egypt
- 10.1.6 South Africa
- 10.2 Middle East and Africa Paroxysmal Nocturnal Hemoglobinuria Treatment by Product
- 10.3 Middle East and Africa Paroxysmal Nocturnal Hemoglobinuria Treatment by End User
11 Company Profiles
- 11.1 Achillion Pharmaceuticals Inc
- 11.1.1 Achillion Pharmaceuticals Inc Company Details
- 11.1.2 Company Business Overview
- 11.1.3 Achillion Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Treatment Sales, Revenue and Gross Margin (2014-2019)
- 11.1.4 Achillion Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Treatment Products Offered
- 11.1.5 Achillion Pharmaceuticals Inc Recent Development
- 11.2 Akari Therapeutics Plc
- 11.2.1 Akari Therapeutics Plc Company Details
- 11.2.2 Company Business Overview
- 11.2.3 Akari Therapeutics Plc Paroxysmal Nocturnal Hemoglobinuria Treatment Sales, Revenue and Gross Margin (2014-2019)
- 11.2.4 Akari Therapeutics Plc Paroxysmal Nocturnal Hemoglobinuria Treatment Products Offered
- 11.2.5 Akari Therapeutics Plc Recent Development
- 11.3 Alexion Pharmaceuticals Inc
- 11.3.1 Alexion Pharmaceuticals Inc Company Details
- 11.3.2 Company Business Overview
- 11.3.3 Alexion Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Treatment Sales, Revenue and Gross Margin (2014-2019)
- 11.3.4 Alexion Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Treatment Products Offered
- 11.3.5 Alexion Pharmaceuticals Inc Recent Development
- 11.4 Alnylam Pharmaceuticals Inc
- 11.4.1 Alnylam Pharmaceuticals Inc Company Details
- 11.4.2 Company Business Overview
- 11.4.3 Alnylam Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Treatment Sales, Revenue and Gross Margin (2014-2019)
- 11.4.4 Alnylam Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Treatment Products Offered
- 11.4.5 Alnylam Pharmaceuticals Inc Recent Development
- 11.5 Amgen Inc
- 11.5.1 Amgen Inc Company Details
- 11.5.2 Company Business Overview
- 11.5.3 Amgen Inc Paroxysmal Nocturnal Hemoglobinuria Treatment Sales, Revenue and Gross Margin (2014-2019)
- 11.5.4 Amgen Inc Paroxysmal Nocturnal Hemoglobinuria Treatment Products Offered
- 11.5.5 Amgen Inc Recent Development
- 11.6 Apellis Pharmaceuticals Inc
- 11.6.1 Apellis Pharmaceuticals Inc Company Details
- 11.6.2 Company Business Overview
- 11.6.3 Apellis Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Treatment Sales, Revenue and Gross Margin (2014-2019)
- 11.6.4 Apellis Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Treatment Products Offered
- 11.6.5 Apellis Pharmaceuticals Inc Recent Development
- 11.7 F. Hoffmann-La Roche Ltd
- 11.7.1 F. Hoffmann-La Roche Ltd Company Details
- 11.7.2 Company Business Overview
- 11.7.3 F. Hoffmann-La Roche Ltd Paroxysmal Nocturnal Hemoglobinuria Treatment Sales, Revenue and Gross Margin (2014-2019)
- 11.7.4 F. Hoffmann-La Roche Ltd Paroxysmal Nocturnal Hemoglobinuria Treatment Products Offered
- 11.7.5 F. Hoffmann-La Roche Ltd Recent Development
- 11.8 ISU ABXIS Co Ltd
- 11.8.1 ISU ABXIS Co Ltd Company Details
- 11.8.2 Company Business Overview
- 11.8.3 ISU ABXIS Co Ltd Paroxysmal Nocturnal Hemoglobinuria Treatment Sales, Revenue and Gross Margin (2014-2019)
- 11.8.4 ISU ABXIS Co Ltd Paroxysmal Nocturnal Hemoglobinuria Treatment Products Offered
- 11.8.5 ISU ABXIS Co Ltd Recent Development
- 11.9 Novartis AG
- 11.9.1 Novartis AG Company Details
- 11.9.2 Company Business Overview
- 11.9.3 Novartis AG Paroxysmal Nocturnal Hemoglobinuria Treatment Sales, Revenue and Gross Margin (2014-2019)
- 11.9.4 Novartis AG Paroxysmal Nocturnal Hemoglobinuria Treatment Products Offered
- 11.9.5 Novartis AG Recent Development
- 11.10 NovelMed Therapeutics Inc
- 11.10.1 NovelMed Therapeutics Inc Company Details
- 11.10.2 Company Business Overview
- 11.10.3 NovelMed Therapeutics Inc Paroxysmal Nocturnal Hemoglobinuria Treatment Sales, Revenue and Gross Margin (2014-2019)
- 11.10.4 NovelMed Therapeutics Inc Paroxysmal Nocturnal Hemoglobinuria Treatment Products Offered
- 11.10.5 NovelMed Therapeutics Inc Recent Development
- 11.11 Omeros Corp
- 11.12 Ra Pharmaceuticals Inc
- 11.13 Regeneron Pharmaceuticals Inc
- 11.14 Regenesance BV
12 Future Forecast
- 12.1 Paroxysmal Nocturnal Hemoglobinuria Treatment Market Forecast by Regions
- 12.1.1 Global Paroxysmal Nocturnal Hemoglobinuria Treatment Sales Forecast by Regions 2019-2025
- 12.1.2 Global Paroxysmal Nocturnal Hemoglobinuria Treatment Revenue Forecast by Regions 2019-2025
- 12.2 Paroxysmal Nocturnal Hemoglobinuria Treatment Market Forecast by Product
- 12.2.1 Global Paroxysmal Nocturnal Hemoglobinuria Treatment Sales Forecast by Product 2019-2025
- 12.2.2 Global Paroxysmal Nocturnal Hemoglobinuria Treatment Revenue Forecast by Product 2019-2025
- 12.3 Paroxysmal Nocturnal Hemoglobinuria Treatment Market Forecast by End User
- 12.4 North America Paroxysmal Nocturnal Hemoglobinuria Treatment Forecast
- 12.5 Europe Paroxysmal Nocturnal Hemoglobinuria Treatment Forecast
- 12.6 Asia Pacific Paroxysmal Nocturnal Hemoglobinuria Treatment Forecast
- 12.7 Central & South America Paroxysmal Nocturnal Hemoglobinuria Treatment Forecast
- 12.8 Middle East and Africa Paroxysmal Nocturnal Hemoglobinuria Treatment Forecast
13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
- 13.1 Market Opportunities and Drivers
- 13.2 Market Challenges
- 13.3 Market Risks/Restraints
- 13.4 Macroscopic Indicators
14 Value Chain and Sales Channels Analysis
- 14.1 Value Chain Analysis
- 14.2 Paroxysmal Nocturnal Hemoglobinuria Treatment Customers
- 14.3 Sales Channels Analysis
- 14.3.1 Sales Channels
- 14.3.2 Distributors
15 Research Findings and Conclusion
16 Appendix
- 16.1 Research Methodology
- 16.1.1 Methodology/Research Approach
- 16.1.2 Data Source
- 16.2 Author Details
Summary:
Get latest Market Research Reports on Paroxysmal Nocturnal Hemoglobinuria Treatment . Industry analysis & Market Report on Paroxysmal Nocturnal Hemoglobinuria Treatment is a syndicated market report, published as Global Paroxysmal Nocturnal Hemoglobinuria Treatment Market Insights, Forecast to 2025. It is complete Research Study and Industry Analysis of Paroxysmal Nocturnal Hemoglobinuria Treatment market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.
REPORT YOU MIGHT BE INTERESTED
Related Reports
Reason to Buy
Reports and Markets
Contact Us
+1-352-353-0818 (US)Newsletter
KEEP UP TO DATE ON ALL THE LATEST REPORTS
